The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...

The FDA's fast track designation for muzastotug with Keytruda targets microsatellite stable metastatic colorectal cancer without liver metastases, based on promising early clinical evidence.

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated ...